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Introduction
The introduction of tumor necrosis factor (TNF) antago-
nists has been a major advance in the treatment of
patients with rheumatoid arthritis (RA). These agents have
been shown to significantly decrease pain, joint swelling,
serologic inflammatory indices, and rates of radiologic
damage [1–6]. In addition, anti-TNF therapy has led to sig-
nificant improvements in physical function and overall
quality of life, as shown by improvements in Health
Assessment Questionnaire (HAQ) scores and as deter-
mined by the Medical Outcomes Study Short-Form Health
Survey (SF-36) [1,5].
All of the TNF antagonists are administered parenterally
[7–9]. Infliximab (Remicade®; Centocor, Inc., Malvern, PA,
USA) is administered intravenously (IV) at an initial dose
of 3mg/kg at weeks 0 (baseline), 2, and 6, then every
8 weeks thereafter. In select patients, the dose can be
increased to 10mg/kg and/or the interval between infu-
sions can be shortened to 4 weeks to optimize response
to therapy [8]. Infliximab is given in combination with oral
methotrexate, usually in an office-based setting [8]. Etan-
ercept (Enbrel®; Immunex Corp, Seattle, WA, USA) is
administered subcutaneously (SC) at a dosage of 25mg
twice weekly [7], and adalimumab (Humira™; Abbott Lab-
oratories, Abbott Park, IL, USA) is planned for SC admin-
istration at a dosage of 40mg every 2 weeks with
methotrexate [9]. Etanercept and adalimumab are primar-
ily self-administered at home, provided that the patient
has no functional limitations.
The difference in routes of administration and dosing regi-
mens between infliximab, etanercept, and adalimumab
raises the question of whether these differences affect
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Abstract
The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers
indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab
are all members of this class, they differ in route of administration and dosing regimen. In the USA and
in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a
dose of 3mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug
Administration (FDA) has further approved that the dosage can be increased to 10mg/kg and the
doses can be given as often as every 4 weeks to optimize patient outcome (information based on the
US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can
be self-injected. The FDA-approved dose of etanercept is 25mg twice weekly, and of adalimumab is
40mg every 2 weeks with methotrexate, or 40mg alone. Medication adherence, possibly the most
important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction
between the patient and his or her healthcare team, the patient’s attitude toward the disease and
medication regimen, and the choice of therapy.
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adherence to therapy and therapeutic outcomes. To
explore this question we examine the experiences of
patients with chronic disorders other than RA.
Relationship between route of administration
and disease outcome
Studies have indicated that the TNF inhibitors seem to
have equivalent short-term efficacies despite the different
routes of administration. However, it is believed that long-
term effectiveness is probably influenced by adherence to
the drug regimen, and poor adherence to long-term thera-
pies can severely compromise the effectiveness of treat-
ment [10]. Efficacy (the extent to which a specific
intervention produces a beneficial effect under ideal con-
ditions) is based mainly on the pharmacologic effects of a
particular therapy, whereas effectiveness (the extent to
which a specific intervention produces a beneficial effect
when used in the community) takes into account many
other aspects, including patient characteristics, health
system attributes, and societal factors [11,12].
Treatment adherence in patients with RA has not been
well studied, but a review of adherence rates to treatment
regimens for other chronic diseases might provide a
logical point of comparison. Among adults and children
who have hypertension, asthma, HIV infection, and
depression, adherence rates to treatments average 50%
worldwide (Table 1) [10].
Adherence, or the lack of it, depends on four factors: (1)
the healthcare team, (2) the disease, (3) the patient, and
(4) the therapy [10].
Factors influencing adherence
Polypharmacy (the prescription of many drugs or ingredi-
ents) has been shown to reduce adherence, especially in
the elderly [13]. Patients who take several drugs or drugs
with multiple dosing or complex regimens are less likely to
take their medications than are patients who take fewer
drugs or drugs with simpler regimens. Provider inconsis-
tency, in which the patient sees a different physician at
each visit, can also limit adherence. Accessibility to physi-
cians and their healthcare staff will enhance adherence to
treatment, as will adequate patient education.
Very limited data are available about the effect of pain and
disability on adherence to therapy in patients with RA [14].
Studies of other chronic diseases such as asthma suggest
that symptom severity might not correlate well with adher-
ence to therapy [15]. Pain, stiffness, and physical deformi-
ties could be relevant if they significantly affect the ability
of the patient to self-inject required medications.
Three patterns of treatment non-adherence have been
observed in patients: (1) erratic non-adherence, often due
to forgetfulness; (2) unwitting non-adherence, due to a
limited understanding of the treatment regimen; and (3)
intelligent non-adherence, in which the patient’s health
beliefs prompt a conscious decision not to adhere to the
treatment. Asthma studies in which medication dosing is
monitored electronically reveal large discrepancies
between self-reported and recorded medication use.
Similar discrepancies exist between patient and physician
reports of medication use [16,17]. In one pediatric asthma
study investigating the self-administration of β-agonists,
inhaled steroids, and cromolyn, respective discordance
rates of 20%, 67%, and 50% were observed between
parents’ reports of their children’s medication use and the
physicians’ actual prescriptions [17].
Poor understanding of the purpose of a medication can
also lead to limited adherence. A Canadian survey of 603
patients with asthma was conducted to determine patient
perceptions of the role of inhaled corticosteroids in
asthma [16]. Results showed that a considerable number
of asthma patients did not understand how corticosteroids
work. Between 41% and 43% of patients believed that
corticosteroids acted to open the airways and relieve con-
striction (which is not true; bronchodilators do this),
whereas only 22% to 24% of patients in this study
believed that corticosteroids reduce inflammation or
swelling of the airways (which they do) [16].
Four factors in patients that have been associated with
poor adherence are denial, disruption, depression, and
dementia. In cases of denial, the patient often believes that
he or she is not sufficiently ill to warrant the prescribed
therapy, which leads to diminished adherence. Disruption
describes any factor, such as a personal or family crisis,
that interrupts the patient’s daily schedule and therefore
his or her medication regimen. Depression often manifests
itself as apathy and not caring about getting well, and
dementia frequently precludes a patient’s ability to follow a
prescribed regimen.
Table 1
Chronic diseases: rates of patient adherence to treatment
regimens
Disease Country Adherence rate (%)
Hypertension USA 51
Gambia 27
Asthma Australia 27–43
HIV/AIDS Worldwide 37–83
Depression USA 40–70
Overall ~50
Data from the World Health Organization [10].S21
The adverse event profile of a therapy, the cost of therapy
and, potentially, the route of administration influence
patient adherence. In addition, failure to respond to a
therapy can limit patient adherence. Unfortunately, the
long-term efficacy and effectiveness of a drug can be
underestimated because of poor patient adherence [12].
Future research will need to focus on RA-specific factors
that affect long-term adherence and the use of monitoring
methods (such as direct observation, electronic monitor-
ing, random home visits, syringe counts, or self-reporting)
to assess patient adherence to injectable drugs.
Subcutaneous versus intravenous dosing
Specific aspects relating to the route of administration
include the onset of efficacy, immunogenicity, and patient
preference. Commonly cited advantages of SC and IV
dosing are listed in Table 2.
SC dosing
Because many SC injections are self-administered, an
advantage of SC dosing is patient control over when and
where the patient will receive his or her medication, and a
lack of associated (namely office-related) costs. In fact,
physicians may prefer SC dosing for patients who would
otherwise have to travel a long distance to receive an IV
infusion.
A disadvantage of SC dosing is limited flexibility; patients
must adhere to specific incremental dosage increases.
There is no flexibility in the dosing of etanercept [7]. It is
not known whether there will be flexibility in the dosing of
adalimumab. In addition, there can be functional limitations
to SC dosing, because not all patients are physically able
to inject themselves, possibly as a result of progressive
RA. Attempts to overcome these limitations include the
development of syringes with bigger wings and larger
caps, and preloaded syringes that do not require reconsti-
tution of the medication (Fig.1). These modifications are
expected to be introduced with adalimumab (data on file,
Abbott Laboratories).
The scientific literature suggests that the likelihood of an
immune response to a biologic agent is greater after SC
administration than after an IV infusion [18]. However, the
rate of anti-product antibody formation, allergic reactions,
efficacy, and the incidence of autoimmune syndromes (for
example, systemic lupus erythematosus) after SC adminis-
tration remain to be determined.
IV dosing
IV dosing allows continuous dosage adjustments to be
made, affording flexibility in matching patient needs at any
given time during the infusion and helping to optimize
overall treatment outcomes. One of the early RA trials with
adalimumab evaluated IV and SC dosing, with double-blind
and open-label phases (Fig.2) (data on file, Abbott Labora-
tories). In the blinded phase, 54 patients were randomized
to receive the study drug IV or placebo SC, the study drug
IV or placebo IV, or the study drug SC or placebo IV, with a
3-week washout period for non-methotrexate disease-mod-
ifying antirheumatic drugs; the second injection was given
at the same dose by the same route after initial response
had faded (no sooner than 4 weeks after the first injection)
(data on file, Abbott Laboratories).
In the open-label phase, patients were given the study
drug SC and were followed for less than 18 months (data
on file, Abbott Laboratories). Overall, the IV and SC
dosing with adalimumab showed similar results in efficacy
endpoints (namely American College of Rheumatology
[ACR]20, ACR50, and European League Against
Rheumatism [EULAR] responses) (data on file, Abbott
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Table 2
Advantages by route of administration
Route Advantages
Subcutaneous Patient control
Lack of associated (such as office-related) costs
No need for patient to travel to office
Intravenous Physician control
Automatic compliance
Dose not limited by volume
Continuous titration available
Rapid onset of action
Reimbursed by Medicare
Figure 1
Syringes with bigger wings and larger caps are designed to make the
self-administration of medication easier.S22
Laboratories). In terms of tender and swollen joint counts,
the IV group showed a more rapid response than the SC
group, whereas the placebo group showed no adequate
response (data on file, Abbott Laboratories).
In terms of reimbursement issues related to the use of
anti-TNF agents in RA, IV dosing might hold an advantage
over SC dosing, especially in patients with Medicare cov-
erage. Generally, coverage for drugs and biologic agents
is provided by Medicare only if such agents (1) meet the
definition of drugs/biologics, (2) are of the type that
cannot be self-administered, (3) meet all general require-
ments for coverage of items as incident to a physician’s
services, (4) are not excluded as immunizations, and (5)
have not been determined by the US Food and Drug
Administration to be less than effective [19].
When selecting a TNF antagonist, the patient’s preference
for route of administration is a significant factor. Jarry and
colleagues [20] conducted a literature review based on
MEDLINE searches to assess the expected compliance
profiles of infliximab and etanercept in patients with RA.
Data about compliance for all parenterally administered
medications in patients with RA and other illnesses were
reviewed. In general, compliance was noted to be poor in
patients with RA regardless of route of administration. In
patients with illnesses other than RA, treatment by means
of assisted IV infusions had higher compliance rates than
self-administered SC injections. A survey that asked which
route of administration for anti-TNF therapy was preferred
by Canadian patients with RA was also conducted.
Results indicated a preference for IV administration (that
is, with infliximab) over an SC regimen (that is, with etaner-
cept). In this survey, factors for this preference included
patients’ general dislike of SC injections, pain and irritation
at the injection site, more frequent administration of the
SC-administered drug (etanercept), difficulty in handling
secure medication containers, and the clinical assistance
attendant on IV administration (Fig.3) [21].
In a study by Tice, more than 95% of outpatients receiving
antibiotics for an infectious disease reported a preference
for IV administration [22]. In addition, it was reported that
70% of cancer chemotherapy is administered IV in an out-
patient setting.
The most common setting for the administration of inflix-
imab is in community-based or academically based clinics.
Other settings include the outpatient section of a hospital,
Arthritis Research & Therapy    Vol 6 Suppl 2 Schwartzman and Morgan
Figure 2
The efficacy of adalimumab (D2E7), as determined by tender and swollen joint counts, could be recognized within 2 weeks when the agent was
injected intravenously (IV) but not until 12 weeks when injected subcutaneously (SC). Baseline values were standardized to 100%. Data on file,
Abbott Laboratories, Abbott Park, IL, USA.
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Figure 3
In a survey of 141 patients with rheumatoid arthritis, 63% indicated a
preference for the administration of medication intravenously (IV) and
37% indicated a preference for administration subcutaneously (SC).
*Preferred someone else to inject the medication. †Preferred self-
injection. Adapted, with permission, from [21].
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independent free-standing infusion units, and the patient’s
home, although most infliximab infusions are administered
outside the home. Some hospitals are introducing immune-
mediated inflammatory disease (IMID) centers, where various
types of disease (for example rheumatic, metabolic, gastroin-
testinal, ophthalmic, neoplastic, hematologic, and infectious)
are managed with IV medications in a single setting.
Healthcare workers who administer IV medications should
be familiar with the toxicities that can occur after infusing
any IV agent and should be able to manage these reac-
tions. Other methods of ensuring safety include the adher-
ence to standardized protocols for the infusion procedure;
patient assessments before, during, and after the proce-
dure; and careful follow-up. Ancillary benefits of IV therapy
include continuity of care, better patient education, peer
support, and access to other medical specialists and
support staff (such as social workers, nutritionists, and
occupational/physical therapists).
Conclusion
In clinical trials the TNF antagonists infliximab, etanercept,
and adalimumab seem to have equivalent short-term effica-
cies despite the different routes of administration of these
agents. However, the long-term efficacy of the TNF antago-
nists in patients with RA is significantly influenced by the
degree of adherence to the therapeutic regimen. Factors
influencing adherence include the healthcare team (for
example, interaction with the patient, patient education), the
disease itself (for example, symptom severity), the patient
(for example, attitude toward therapy), and the therapy
chosen (for example, potential adverse events, cost, route of
administration). Does the route of administration influence
the outcomes of anti-TNF therapy? There are indications
that it might, although this question needs to be evaluated
qualitatively and quantitatively by further research.
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